TARGT IndiegeneTM is one of the largest cancer gene panels in the world developed by comprehensively profiling the whole-exome and transcriptome of 1500+ tumor samples across 28 cancer types covering well-known oncogenic driver mutations and other oncogenic variations having clinical and research value.
TARGT IndiegeneTM analyzes 1212 unique genes, including 1064 genes for SNVs/Indels, 570 genes for CNAs, and 299 genes associated with Gene-Fusions, which include common and rare fusions as well as novel fusion partners along with Immunotherapy Biomarkers (TMB, MSI by NGS, and PD-L1 by IHC).
Furthermore, TARGT IndiegeneTM offers two additional options: TARGT IndiegeneTM Liquid, a liquid biopsy panel, and TARGT IndiegeneTM Pro, which combines solid and liquid biopsies. These approaches utilize both sample sources to overcome their limitations and provide a comprehensive view of the disease's genomic landscape, leading to the optimal resolution.
Benefits of TARGT IndiegeneTM Gene Panel Testing
Clinically Actionable Insights
This gene panel provides oncologists with clinically actionable insights from individual patients’ tumor tissue. The detailed genetic information obtained through this gene panel testing allows oncologists to make informed treatment decisions.
Identification of Novel Fusion Partners
This gene panel includes common and rare gene fusions and identifies novel fusion partners. This aspect of the gene panel testing is particularly valuable as it expands the understanding of fusion events in cancer, potentially uncovering new therapeutic targets or diagnostic markers that were previously unknown.
Inclusion of Immunotherapy Biomarkers
This gene panel goes beyond genetic alterations by incorporating immunotherapy biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and programmed death-ligand 1 (PD-L1) expression. These biomarkers play a crucial role in predicting response to immune checkpoint inhibitors, a cancer treatment that has shown remarkable success in certain patients.
Research Value
This gene panel holds significant research value besides its clinical applications. The panel covers well-known oncogenic driver mutations and rare and novel fusions, providing researchers with valuable data for studying cancer development and progression mechanisms.
Why Choose 4baseCare's TARGT IndiegeneTM Cancer Gene Panel?
Comprehensive Analysis
Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.
Advanced Technology
We utilize cutting-edge genomic sequencing technologies to deliver precise and detailed genetic information.
Expert Team
Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.
Confidentiality and Privacy
We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.